专利号:US-9353057-B2 优先权日:2003-12-30 标 题:Synthesis of acyloxyalkyl carbamate prodrugs and intermediates thereof 发明人:GALLOP MARK A; DAI XUEDONG; SCHEUERMAN RANDALL A; RAILLARD STEPHEN P; MANTHATI SURESH K; YAO FENMEI; PHAN THU; LUDWIKOW MARIA; PENG GE; BHAT SEEMA 权利人:XENOPORT INC 摘要:Methods for synthesis of 1-(acyloxy)-alkyl carbamates, particularly, the synthesis of 1-(acyloxy)-alkyl carbamate prodrugs of primary or secondary amine-containing drugs are described. Also described are methods for synthesis of 1-(acyloxy)-alkyl N-hydroxysuccinimidyl carbonates which are useful intermediates in the synthesis of 1-(acyloxy)-alkyl carbamates are also described.
专利号:US-2008287407-A1 优先权日:2003-12-10 标题 :Nitric Oxide Releasing Pyruvate Compounds, Compositions and Methods of Use 发明人:GARVEY DAVID S; FANG XINQIN; KHANAPURE SUBHASH P; RANATUNGA RAMANI R; WEY SHIOW-JYI 权利人:NITROMED INC 摘要:The invention describes novel nitrosated and/or nitrosylated pyruvate compounds and pharmaceutically acceptable salts thereof, and novel compositions comprising at least one nitrosated and/or nitrosylated pyruvate compound, and, optionally, at least one compound that donates, transfers or releases nitric oxide, stimulates endogenous synthesis of nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor or is a substrate for nitric oxide synthase, and/or at least one therapeutic agent. The invention also provides novel compositions comprising at least one pyruvate compound and at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase and/or at least one therapeutic agent. The invention also provides novel kits comprising at least one pyruvate compound, that is optionally nitrosated and/or nitrosylated, and, optionally, at least one nitric oxide donor and/or at least one therapeutic agent. The invention also provides methods for treating diseases resulting from oxidative stress, diabetes, reperfusion injury following ischemia, preservation of tissues, organs, organ parts and/or limbs.
专利号:US-2015158809-A9 优先权日:2013-02-26 标 题 :Method of making 1-(acyloxy)-alkyl carbamate compounds 发明人:WANG HUAN; LIU PENG; DAI QUNYING; YIN HAO; RAILLARD STEPHEN P 权利人:XENOPORT INC 摘要:Methods of preparing carbamate prodrugs of amine-containing drugs are provided. Carbonates useful in the synthesis of the carbamate prodrugs are also provided.
专利号:US-2025223262-A1 优先权日:2022-03-31 标 题 :Synthesis of morphinans with reduced herg activity and mop binding 发明人:LAMMERT ECKHARD; SCHOLZ OKKA; OTTER SILKE; HEREBIAN DIRAN; HOFFMANN TORSTEN; SANZ MIGUEL ANGEL; KRAMP LAURENZ; LEVY LAURA MARIANA; HRISTEVA STANIMIRA 权利人:HEINRICH HEINE UNIV DUESSELDORF; DEUTSCHE DIABETES FORSCHUNGSGESELLSCHAFT E V; TAROS CHEMICALS GMBH & CO KG 摘要:The invention relates to morphinan-derivatives, processes for their preparation, medicaments containing them and the use of these morphinan-derivatives for the preparation of medicaments.
专利号:US-8183409-B2 优先权日:2004-05-06 标题:High yield and rapid synthesis methods for producing metallo-organic salts 发明人:CHRISTGAU STEPHAN; ANDERSEN JENS E T 权利人:CHRISTGAU STEPHAN; ANDERSEN JENS E T; OSTEOLOGIX AS 摘要:A new method for preparing salts of metal cations and organic acids, especially divalent salts of alkaline earth metal ions from group II of the periodic system and carboxylic acids. The method comprising the use of a high temperature (about 90° or more) and, optionally. high pressure, in order to obtain a higher yield, purity and faster reaction speed than obtained with known synthesis methods. In particular, the present invention relates to the production of strontium salts of carboxylic acids. Novel strontium salts are also provided by the present method.
专利号:US-2007287734-A1 优先权日:2006-06-09 标 题 :Preparation and utility of substituted pyrazole compounds with cannabinoid receptor activity 发明人:GANT THOMAS G; SARSHAR SEPEHR 权利人:AUSPEX PHARMACEUTICALS INC 摘要:The present disclosure is directed to modulators of CB-1 type receptors and pharmaceutically acceptable salts and prodrugs thereof, the chemical synthesis thereof, and the medical use of such compounds for the treatment and/or management of the severity and duration of obesity, metabolic syndrome, dyslipidemia, glucose imbalance, the inability to maintain weight loss, insulin resistance, a cardiovascular disorder, memory loss, drug dependence, a depressive disorder, a panic disorder, an obsessive-compulsive disorder, anxiety, post-traumatic stress syndrome, and any other condition in which it is beneficial to inhibit, inversely agonize or modulate a cannabinoid receptor are described.
1: Bano S, Ahmed FW, Saeed A, Nawazish A, Haris M, Mansoor A, Jamali AG, Ahmed R, Khan SH, Akram N, Salahuddin Z, Umar M, Abufatima IO. Efficacy and safety of Tirofiban following intravenous thrombolysis: a systematic review and meta- analysis of randomized controlled trials. BMC Neurol. 2026 Apr 17. doi: 10.1186/s12883-026-04892-8. Epub ahead of print. 105(16):e48070. doi: 10.1097/MD.0000000000048070. 4: Lu X, Cao L, Zeng L, Zhang L. Tirofiban combined with aspirin for branch atheromatous disease: a propensity score-matched study. Front Neurol. 2026 Apr 1;17:1802990. doi: 10.3389/fneur.2026.1802990. 5: A A, P A, Subramani S, V R. Comment on "Leukoaraiosis in patients with tirofiban before endovascular thrombectomy: A post hoc analysis of a multicentre randomized clinical trial". J Formos Med Assoc. 2026 Apr
合成参考文献
摘要:Zhao JL, Yang YJ, Wu YJ, Jing ZC, You SJ, Yang WX, Meng L, Tian Y, Chen JL, Gao RL, Chen ZJ. [Effects of anti-platelet drugs on myocardial no-reflow after acute myocardial infarction and reperfusion: experiment with mini-swine model]. Zhonghua Yi Xue Za Zhi. 2005 Aug 17;85(31):2187–91. 参考文献:10.2174/1874205x01105010048 摘要:Rossi P, Mandelli C, Manganaro D, Zecca B, Maestroni A, Monzani V, Torgano G. A Spontaneous Decrease of Blood Pressure Occurs in Acute Ischemic Stroke with Favourable Neurological Course. TONEUJ. 2011 Jun 21;05(1):48–54. doi: 10.2174/1874205x01105010048. 参考文献:10.1155/2011/250518 摘要:Tufano A, Cimino E, Di Minno MND, Ieranò P, Marrone E, Strazzullo A, Di Minno G, Cerbone AM. Diabetes Mellitus and Cardiovascular Prevention: The Role and the Limitations of Currently Available Antiplatelet Drugs. International Journal of Vascular Medicine. 2011;2011():1–5. doi: 10.1155/2011/250518. 参考文献:10.4244/eijv7i4a68 摘要:Valgimigli M. AMI on the move. EuroIntervention. 2011 Aug;7(4):415, 417, 419. doi: 10.4244/eijv7i4a68. 参考文献:10.4244/eijv7i4a73 摘要:Heestermans T, de Boer MJ, van Werkum JW, Mosterd A, Gosselink AT, Dambrink JH, van Houwelingen G, Koopmans P, Hamm C, Zijlstra F, ten Berg JM, van 't Hof AW. Higher efficacy of pre-hospital tirofiban with longer pre-treatment time to primary PCI: protection for the negative impact of time delay. EuroIntervention. 2011 Aug;7(4):442–8. doi: 10.4244/eijv7i4a73.